Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes Awarded more than $25 million from the California
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic
Scribe received multi-year grant awards from the California Institute for Regenerative Medicine (CIRM) to advance two therapeutic programs from Scribe’s comprehensive, wholly-owned cardiometabolic portfolio Preclinical programs supported by the awards, STX-1200 and STX-1400, have the potential to
Late-breaking oral presentation at EAS Congress 2026 reports up to 90% PCSK9 reduction and up to 68% LDL-C lowering, with the lowest dose achieving >50% LDL-C reduction for >22 months and ongoing, in non-human primates with a clean tolerability profile These data support STX-1150’s recent
ALAMEDA, Calif., May 21, 2026 – Scribe Therapeutics, Inc. (Scribe) a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that it has secured
ASGCT oral presentations to showcase recent development in engineering highly specific and potent CRISPR gene editing and epigenetic silencing technologies Late-breaking EAS oral presentation to report latest preclinical data for PCSK9-silencing therapy STX-1150 for ASCVD ALAMEDA, Calif., April
Milestone achieved in Scribe and Lilly’s ongoing collaboration to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular diseases Achievement validates Scribe’s technologies and strengthens momentum across its genetic medicine portfolio, including its internal pipeline